Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Moriniere

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Clinical Nephrology|June 1, 1988
Magnesium hydroxide is a useful complementary aluminum-free phosphate binder to moderate doses of oral calcium in uremic patients on chronic hemodialysisA Fournier, P Moriniere
Presse Medicale (Paris, France : 1983)|October 4, 1986
[Does the use of ticlopidine in chronic hemodialysed patients contra- indicate renal transplantation? A false problem?]P Moriniere, T Pourchez, H Renaud
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 1, 1992
Dialysate calcium reduction in CAPD patients treated with CaCO3 alone or CaCO3 and 1 alpha OH vitamin D3A Fournier, N el Elśper, P Moriniere
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 1, 1996
Low doses of calcitriol or calcium carbonate for the prevention of hyperparathyroidism in predialysis patients?A Fournier, R Oprisiu, P Moriniere, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 1, 1994
CaCO3: an inefficient and unsafe phosphate binder?A Fournier, P Moriniere, F B Hamida, et al.
Therapie|September 12, 1998
[Is hemodialysis a risk factor for tendinopathies due to fluoroquinolones?]G Decoq, P Moriniere, I Dufour, et al.
BMJ (Clinical Research Ed.)|July 8, 1995
Effect of alfacalcidol on renal bone disease in mild to moderate renal failure. Questions remain over alfacalcidol's efficacy in preventing secondary hyperparathyroidismA Fournier, N E Esper, P Moriniere, et al.
Nephrologie|January 1, 1983
[Hyperaluminemia in chronic hemodialysis patients. Evaluation of the respective roles of dialysate aluminum and oral aluminum hydroxide]Y Tahiri, P Moriniere, M C Jaudon, et al.
Artificial Organs|July 31, 1998
Heparin-induced hyperkalemia in chronic hemodialysis patients: comparison of low molecular weight and unfractionated heparinC Hottelart, J M Achard, P Moriniere, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 7, 2001
Sevelamer, Ca x P product and vitamin DA Fournier, J Barsoum, R Fickl, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Clinical Nephrology|June 1, 1988
Magnesium hydroxide is a useful complementary aluminum-free phosphate binder to moderate doses of oral calcium in uremic patients on chronic hemodialysisA Fournier, P Moriniere
Presse Medicale (Paris, France : 1983)|October 4, 1986
[Does the use of ticlopidine in chronic hemodialysed patients contra- indicate renal transplantation? A false problem?]P Moriniere, T Pourchez, H Renaud
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 1, 1992
Dialysate calcium reduction in CAPD patients treated with CaCO3 alone or CaCO3 and 1 alpha OH vitamin D3A Fournier, N el Elśper, P Moriniere
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 1, 1996
Low doses of calcitriol or calcium carbonate for the prevention of hyperparathyroidism in predialysis patients?A Fournier, R Oprisiu, P Moriniere, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 1, 1994
CaCO3: an inefficient and unsafe phosphate binder?A Fournier, P Moriniere, F B Hamida, et al.
Therapie|September 12, 1998
[Is hemodialysis a risk factor for tendinopathies due to fluoroquinolones?]G Decoq, P Moriniere, I Dufour, et al.
BMJ (Clinical Research Ed.)|July 8, 1995
Effect of alfacalcidol on renal bone disease in mild to moderate renal failure. Questions remain over alfacalcidol's efficacy in preventing secondary hyperparathyroidismA Fournier, N E Esper, P Moriniere, et al.
Nephrologie|January 1, 1983
[Hyperaluminemia in chronic hemodialysis patients. Evaluation of the respective roles of dialysate aluminum and oral aluminum hydroxide]Y Tahiri, P Moriniere, M C Jaudon, et al.
Artificial Organs|July 31, 1998
Heparin-induced hyperkalemia in chronic hemodialysis patients: comparison of low molecular weight and unfractionated heparinC Hottelart, J M Achard, P Moriniere, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 7, 2001
Sevelamer, Ca x P product and vitamin DA Fournier, J Barsoum, R Fickl, et al.
Pageof 4